1 |
Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin 2016;32(6):631-9.
|
2 |
Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.
DOI
|
3 |
Thompson PD, Panza G, Zaleski A, et al. Statin-associated side effects. J Am Coll Cardiol 2016;67(20):2395-410.
DOI
|
4 |
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25):2889-934.
DOI
|
5 |
Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350(15):1495-504.
DOI
|
6 |
de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292(11):1307-16.
DOI
|
7 |
Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 2007;93(8):914-21.
DOI
|
8 |
Cannon CP, Steinberg BA, Murphy SA, Mega JL, et al. Metaanalysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48(3):438-45.
DOI
|
9 |
Silva M, Matthews ML, Jarvis C, et al. Meta-analysis of druginduced adverse events associated with intensive-dose statin therapy. Clin Ther 2007;29(2):253-60.
DOI
|
10 |
Korea Institute of Drug Safety & Risk Management. KIDS-KD manual ver 3.0 [Internet]. Korea Institute of Drug Safety & Risk Management;2016. Available from https://www.drugsafe.or.kr/iwt/ds/ko/bbs/EgovBbs.do?bbsId=BBSMS TR_000000000291&nttId=1749&pageIndex=1&searchCnd=&searchWrd=. Accessed July, 23 2018.
|
11 |
WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2013 [Internet]. Oslo:WHO Collaborating Centre for Drug Statistics Methodology;2012. Available from https://www.whocc.no/filearchive/publications/1_2013guidelines.pdf. Accessed July 23, 2018.
|
12 |
World Health Organization. The WHO Adverse Reaction Terminology (WHO-ART) 2005 [Internet]. World Health Organization;2017 Available from https://www.who-umc.org/whodrug/whodrug-portfolio. Accessed July 23, 2018.
|
13 |
Statistics Korea. Korean Standard Classification of Diseases and Causes of Death (KCD-6) [Internet]. Daejeon: Statistics Korea; 2011. Available from http://www.kcdcode.co.kr/browse/main/Accessed 23 July, 2018.
|
14 |
The use of the WHO-UMC system for standardized case causality assessment. World Health Organization (WHO)-Uppsala Monitoring Centre. Available from http://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf. Accessed July 23, 2018.
|
15 |
Yu YM, Shin WG, Lee JY, et al. Patterns of adverse drug reactions in different age groups: analysis of spontaneous reports by community pharmacists. PLoS One 2015;10(7):e0132916.
DOI
|
16 |
Dweik RA, Yaya S, Stacey D, Kohen D. Spontaneous adverse drug reaction reporting by patients in Canada: a multi-method studystudy protocol. Springerplus 2016;5:213.
DOI
|
17 |
Lee MW, Lee JS, Han OY, et al. Study for association between adverse drug reactions and causative drugs in the elderly using datamining analysis. Korean J Clin Pharm 2014;24(1):39-44.
|
18 |
Lee J, Noh Y, Shin S, et al. Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claimsdatabase. Ther Clin Risk Manag 2016;12:1533-43.
DOI
|
19 |
Akimoto H, Negishi A, Oshima S, et al. Onset timing of statininduced musculoskeletal adverse events and concomitant drugassociated shift in onset timing of MAEs. Pharmacol Res Perspect 2018;6(6):1-9.
|
20 |
Lexicomp Online, Atoravstatin adverse reactions, Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2013; Available from http://www.lexicomponline.com/lco/action/doc/retrieve/docid/multinat_f/4668926#f_adverse-reactions. Accessed July 23, 2018).
|
21 |
Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97(8A):77C-81C.
|
22 |
Escobar C, Echarri R, Barrios V. Relative safety profiles of high dose statin regimens. Vasc health risk manag 2008;4(3):525-33.
DOI
|
23 |
Jose J. Statins and its hepatic effects: Newer data, implications, and changing recommendations. J Pharm Bioallied Sci 2016;8(1):23-8.
DOI
|
24 |
Davidson MH, Clark JA, Glass LM, et al. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol 2006;97(8A):32C-43C.
DOI
|
25 |
Dobritoiu AM, Forsea DG. Statins and the skin. Ther Pharmacol Clin Toxicol 2011;15:98-104.
|
26 |
Salna MP, Singer HM, Dana AN. Pravastatin-induced eczematous eruption mimicking psoriasis. Case Rep Dermatol Med 2017;2017:3418204.
|
27 |
Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005;19(6):403-14.
DOI
|
28 |
Escobar C, Echarri R, Barrios V. Relative safety profiles of high dose statin regimens. Vasc health risk manag 2008;4(3):525-33.
DOI
|
29 |
Collins GS, Altman DG. Predicting the adverse risk of statin treatment: an independent and external validation of Qstatinrisk scores in the UK. Heart 2012;98(14):1091-7.
DOI
|
30 |
Nguyen KA, Li L, Lu D, et al. A comprehensive review and metaanalysis of risk factors for statin-induced myopathy. Eur J Clin Pharmacol 2018;74(9):1099-109.
DOI
|
31 |
James K. Liao. Safety and Efficacy of Statins in Asians. Am J Cardiol 2007;99(3):410-4.
DOI
|
32 |
Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005;165(12):1363-9.
DOI
|
33 |
Lee SW, Lee J, Kim NH, et al. Pruritus induced by multiple statins: a case report. JPERM 2017;9:41-4.
|